- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02255760
Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults
November 22, 2017 updated by: MedImmune LLC
A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of MEDI3902 in Healthy Adults
This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study evaluating the safety and tolerability of a single ascending IV dose of MEDI3902 in healthy adult subjects 18 to 60 years of age.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This is a Phase 1, randomized, double-blind, placebo-controlled, dose escalation study evaluating the safety and tolerability of a single ascending IV dose of MEDI3902 in healthy adult subjects 18 to 60 years of age.
Approximately 40 subjects will be enrolled across 4 fixed dose cohorts at 1 study site.
This study will last approximately 90 days, constituting a screening period of up to 28 days, 1 day of investigational product administration, and a 60 day safety follow up period.
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
South Miami, Florida, United States, 33143
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18 through 60 years at the time of screening
- Written informed consent
- Weight greater than or equal to (>=) 45 kilogram (kg) and less than or equal to (<=) 110 kg at screening
- Healthy by medical history, physical examination, and baseline safety laboratory studies
- Systolic blood pressure (BP) less than (<) 140 millimeter of mercury (mmHg) and diastolic BP < 90 mmHg at screening
- Electrocardiogram (ECG) without clinically significant abnormalities at screening
- Able to complete the follow-up period through Day 61 as required by the protocol.
- Females of childbearing potential who are sexually active with a nonsterilized male partner must have used a highly effective method of contraception for at least 28 days prior to dosing with investigational product and must agree to continue using such precautions through Day 61 of the study.
Exclusion Criteria:
- Acute (time-limited) illness, including fever 99.5 degree Fahrenheit (0^F), on day prior to or day of planned dosing
- Any drug therapy within 7 days prior to Day 1 (except contraceptives or a single use of acetaminophen, aspirin, antihistamine, or combination over-the-counter (OTC) product that contains acetaminophen with an antihistamine, or OTC non-steroidal anti inflammatory agent at a dose equal to or lower than that recommended on the package). Vitamins and other nutritional supplements that are not newly introduced, ie, have been taken for at least 30 days prior to enrolment, are not exclusionary
- Blood drawn in excess of a total of 450 mL (1 unit) for any reason within 2 months prior to screening
- Receipt of immunoglobulin or blood products within 6 months prior to screening
- Receipt of any investigational product in the preceding 90 days or expected receipt of investigational product during the period of study follow-up, or concurrent participation in another interventional study Receipt of any vaccine within 7 days prior to investigational product dosing or planned receipt within 61 days after investigational product dosing except for influenza vaccine administered at least 28 days after dosing
- Previous receipt of a mAb
- Immunodeficiency due to illness, including human immunodeficiency virus (HIV) infection, or due to drugs, including any course of glucocorticoid therapy exceeding 2 weeks of prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months prior to screening. HIV testing must be negative at screening
- History of allergic disease or reactions likely to be exacerbated by any component of the investigational product
- Either history of active infection with hepatitis B or C
- Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or serum creatinine above the upper limit of normal (ULN) or hemoglobin, white blood cell count, or platelet count below the lower limit of normal at screening and in the predose blood sample
- Pregnant or nursing mother
13. History of alcohol or drug abuse within the past 2 years.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MEDI3902 - Dose 1
Participants will receive a single intravenous (IV) dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
|
Participants will receive a single IV dose of MEDI3902 infused for a minimum of 13 minutes on Day 1.
Other Names:
|
Experimental: MEDI3902 - Dose 2
Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
|
Participants will receive a single IV dose of MEDI3902 infused for a minimum of 38 minutes on Day 1.
Other Names:
|
Experimental: MEDI3902 - Dose 3
Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
|
Participants will receive a single IV dose of MEDI3902 infused for a minimum of 75 minutes on Day 1.
Other Names:
|
Experimental: MEDI3902 - Dose 4
Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
|
Participants will received a single IV dose of MEDI3902 infused for a minimum of 150 minutes on Day 1.
Other Names:
|
Placebo Comparator: Placebo
Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
|
Participants will receive a single dose of placebo by IV infusion up to a maximum of 12 hours.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Day 1 to Day 29
|
An adverse event (AE) is any unfavourable and unintended sign, symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug.
A TEAE is defined as events present at baseline that worsened in intensity after administration of study drug or events absent at baseline that emerged after administration of study drug.
|
Day 1 to Day 29
|
Number of Participants With Treatment-Emergent Serious Adverse Events (TESAEs) and Treatment Emergent Adverse Events of Special Interest (TEAESIs)
Time Frame: Day 1 to Day 61
|
An AE is any untoward medical occurrence attributed to study drug in a participant who received investigational product.
TESAE was an event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly that occurred after the initial receipt of the study drug.
An AESI was one of scientific and medical interest specific to understanding of study product and may have required close monitoring and rapid communication by investigator to the sponsor.
TEAESIs were collected from the time of dosing through Day 61 after the last dose of study drug and included anaphylaxis, other serious allergic reactions, infusion-related reactions, hepatic function abnormalities and immune complex disease.
|
Day 1 to Day 61
|
Number of Participants With Abnormal Clinical Laboratory Parameters Reported as Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Day 1 to Day 29
|
Any medically significant change in laboratory evaluations were recorded as adverse events.
Following parameters were analyzed for laboratory examination: Hematology, serum chemistry, liver function, serum electrolytes and urinalysis.
|
Day 1 to Day 29
|
Number of Participants With Abnormal Vital Signs Reported as Treatment-Emergent Adverse Events (TEAEs)
Time Frame: Day 1 to Day 7
|
Vital signs measurements included temperature, blood pressure (systolic and diastolic), pulse rate and respiratory rate.
|
Day 1 to Day 7
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area Under the Serum Concentration-time Curve From Zero to Infinity (AUC [0-infinity])
Time Frame: Pre-dose (24 hours prior to dose); at the end of the infusion, and 8 hours post infusion, and Days 2, 3, 7, 15, 22, 29, 43, and 61 post-dose
|
Area under the serum concentration versus time curve (AUC) from time zero (predose) to extrapolated infinite time (0 - infinity).
The PK parameter AUC (0-inf) was estimated based on the serum concentrations of MEDI3902.
Non-compartmental PK data analysis was performed to estimate the serum PK parameters of MEDI3902.
|
Pre-dose (24 hours prior to dose); at the end of the infusion, and 8 hours post infusion, and Days 2, 3, 7, 15, 22, 29, 43, and 61 post-dose
|
Maximum Observed Serum Concentration (Cmax) for MEDI3902 After First Dose
Time Frame: Pre-dose (24 hours prior to dose); at the end of the infusion, and 8 hours post infusion, and Days 2, 3, 7, 15, 22, 29, 43, and 61 post-dose
|
The PK parameter Cmax was estimated based on the serum concentrations of MEDI3902.
Non-compartmental PK data analysis was performed to estimate the serum PK parameters of MEDI3902.
|
Pre-dose (24 hours prior to dose); at the end of the infusion, and 8 hours post infusion, and Days 2, 3, 7, 15, 22, 29, 43, and 61 post-dose
|
Terminal Phase Elimination Half-life (t1/2)
Time Frame: Pre-dose (24 hours prior to dose); at the end of the infusion, and 8 hours post infusion, and Days 2, 3, 7, 15, 22, 29, 43, and 61 post-dose
|
The t1/2 is the time measured for the serum drug concentration of MEDI3902 to decrease by one half.
The PK parameter t1/2 was estimated based on the serum concentrations of MEDI3902.
Non-compartmental PK data analysis was performed to estimate the serum PK parameters of MEDI3902.
|
Pre-dose (24 hours prior to dose); at the end of the infusion, and 8 hours post infusion, and Days 2, 3, 7, 15, 22, 29, 43, and 61 post-dose
|
Volume of Distribution at Steady State (Vss)
Time Frame: Pre-dose (24 hours prior to dose); at the end of the infusion, and 8 hours post infusion, and Days 2, 3, 7, 15, 22, 29, 43, and 61 post-dose
|
Volume of distribution is defined as the theoretical volume in which the total amount of drug uniformly distributed to produce the desired serum concentration of a drug.
The PK parameter Vss was estimated based on the serum concentrations of MEDI3902.
Non-compartmental PK data analysis was performed to estimate the serum PK parameters of MEDI3902.
|
Pre-dose (24 hours prior to dose); at the end of the infusion, and 8 hours post infusion, and Days 2, 3, 7, 15, 22, 29, 43, and 61 post-dose
|
MEDI3902 Serum Clearance (CL) of MEDI3902
Time Frame: Pre-dose (24 hours prior to dose); at the end of the infusion, and 8 hours post infusion, and Days 2, 3, 7, 15, 22, 29, 43, and 61 post-dose
|
Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.
The PK parameter CL was estimated based on the serum concentrations of MEDI3902.
Non-compartmental PK data analysis was performed to estimate the serum PK parameters of MEDI3902.
|
Pre-dose (24 hours prior to dose); at the end of the infusion, and 8 hours post infusion, and Days 2, 3, 7, 15, 22, 29, 43, and 61 post-dose
|
Number of Participants With Positive Anti-drug Antibody (ADA) to MEDI3902
Time Frame: Days 1 (pre-dose), 15, 29, and 61
|
Blood samples were collected to evaluate the antidrug antibody responses to MEDI3902 in serum.
The number of participants positive for serum antibodies to MEDI3902 were presented.
|
Days 1 (pre-dose), 15, 29, and 61
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Hasan S. Jafri, M.D., MedImmune LLC
- Principal Investigator: Martha Hernandez-Illas, MD, MRA Clinical Research, LLC
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 4, 2014
Primary Completion (Actual)
April 20, 2015
Study Completion (Actual)
April 20, 2015
Study Registration Dates
First Submitted
September 16, 2014
First Submitted That Met QC Criteria
October 2, 2014
First Posted (Estimate)
October 3, 2014
Study Record Updates
Last Update Posted (Actual)
August 13, 2018
Last Update Submitted That Met QC Criteria
November 22, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- D5470C00002
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MEDI3902 for Prevention of P. Aeruginosa Pneumonia
-
Wafaa Uthman AhmedAin Shams Maternity HospitalUnknownCARBETOCIN FOR PREVENTION OF PLACENTAL RETAINEDEgypt
-
Shanghai Children's Medical CenterNot yet recruitingTo Analyze and Compare the Efficacy and Safety of Ondansetron and Tablet for the Prevention of Moderate and Hypoemetic Chemotherapy
-
Novartis PharmaceuticalsCompletedTreatment of Early Pulmonary Infections With P. Aeruginosa in Cystic Fibrosis PatientsEgypt, Greece, Hungary, Russian Federation, Canada, Germany, France, Italy, Switzerland, Romania
-
AmgenCompletedTreatment for Prevention of Chronic MigraineUnited States, United Kingdom, Poland, Germany, Czechia, Sweden, Canada, Denmark, Finland, Norway
-
AmgenCompletedTreatment for Prevention of Chronic MigraineUnited States, United Kingdom, Poland, Germany, Czechia, Sweden, Canada, Denmark, Finland, Norway
-
University of SaskatchewanGovernment of Canada; Vaccine Formulation Institute (VFI); Government of Saskatchewan and other collaboratorsActive, not recruitingDouble Vaccinated for COVID-19 (For Phase 1 of the Study) | Acute Respiratory Syndrome Coronavirus 2 (For Phase 2 Exploratory Group)Canada
-
PfizerCompletedPrevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnCIndia
-
Cao WeijieRecruitingLetemovir for the Prevention of CMV Infection After Allo-HSCTChina
-
The Cleveland ClinicCompletedPrevention of COVID-19United States
-
Calmy AlexandraCompletedPrevention of COVID-19Switzerland, Brazil
Clinical Trials on MEDI3902 - Dose 1
-
MedImmune LLCNational Institute of Allergy and Infectious Diseases (NIAID); Antibacterial... and other collaboratorsCompletedPseudomonas AeruginosaSpain, United States, Belgium, France, Hungary, United Kingdom, Israel, Austria, Portugal, Greece, Czechia, Turkey, Croatia, Ireland
-
Medy-ToxCompletedLateral Canthal Lines | Glabellar LinesUnited States, Russian Federation, Germany, Canada, Belgium, United Kingdom
-
Zensun Sci. & Tech. Co., Ltd.Zensun USA Inc.CompletedChronic Heart FailureUnited States
-
Astellas Pharma Europe B.V.CompletedPharmacokinetics of ASP1707 | Pharmacodynamics of ASP1707France
-
Virginia Commonwealth UniversityGilead SciencesWithdrawnChronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | CLL | Refractory Small Lymphocytic Lymphoma | SLL | Relapsed CLL | Relapsed Chronic Lymphocytic Leukemia | Relapsed Small Lymphocytic Lymphoma
-
Oryn Therapeutics, LLCCompletedRheumatoid ArthritisUnited States
-
Loyola UniversityNational Cancer Institute (NCI)Active, not recruiting
-
Institute of Medical Biology, Chinese Academy of...Guangxi Center for Disease Control and PreventionCompleted
-
Renibus Therapeutics, Inc.CompletedAKIUnited States, Australia, Canada
-
Aronora, Inc.CompletedThrombosis | End Stage Renal DiseaseUnited States